In contrast to other molecular types of breast cancer, TNBC shows higher PD-L1 expression and immune cell infiltration, suggesting that patients with TNBC may benefit from immunotherapy, despite its limited efficacy due to the lack of infiltrating effector lymphocytes [5]. Here, CD274 is linked to breast carcinoma.